CompletedNCT04232644
ADAIR: Safety and Abuse Potential of a Deterrent Medicine
About this title
Read the official source — NCT04232644Medication studyAges 18–55CanadaADHD
Understand this study
Who was this study for?
Listed age limits: 18 years to 55 years.
- Listed locations
- TorontoSee all locations and recruitment
- Study phase
- Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
Study information
Study start dateStarted: May 27, 2019
- Recruitment status
- Completed
- Enrollment listed in the registry
- 16
- Sponsor
- Vallon Pharmaceuticals, Inc.
- Sponsor type
- Other organization
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
- Locations
- Canada
- Age range
- From 18 Years to 55 Years
- Official registry ID
- NCT04232644
- Official title
Show the full official title
A Pilot, Randomized, Double-Blind, Active-Controlled, 2-Treatment, Crossover Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Abuse Liability of Dextroamphetamine Sulfate From an Abuse-Deterrent Immediate-Release Formulation (ADAIR)
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Toronto
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Vallon Pharmaceuticals, Inc.
Did this study involve medication?
Yes. The study involved medication, including ADAIR 10mg IR capsules and Crushed d-amphetamine sulfate IR tablets.
Who was this study for?
Listed age limits: 18 years to 55 years.
